Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of medical composition in preparation of drug for preventing or treating ischemia retinae

A pharmaceutical composition, retinal ischemia technology, applied in the direction of drug combination, pharmaceutical formula, medical preparations containing active ingredients, etc., can solve problems such as poor visual results

Inactive Publication Date: 2018-11-02
赵效明
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Anti-VEGF antibodies are used clinically all over the world, but they are not completely effective in the treatment of vision-threatening retinal diseases, such as proliferative diabetic retinopathy (proliferative diabetic retinopathy, PDR), wet age-related macular degeneration (wet age- related macular degeneration (wAMD) and central / branch retinal vein or artery occlusion
In addition, patients administered anti-VEGF agents exhibited poor visual outcomes even after successful drying of the vitreous / subretinal hemorrhage and macular edema

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medical composition in preparation of drug for preventing or treating ischemia retinae
  • Application of medical composition in preparation of drug for preventing or treating ischemia retinae
  • Application of medical composition in preparation of drug for preventing or treating ischemia retinae

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1. The effect of Xuefu Zhuyu Decoction on the b-wave of retinal electrogram.

[0033] The experimental animals were handled in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmology and Vision Research, and all animal experiments were approved by Zhenxing Hospital Animal Care and Use The committee agreed (CHGH; Taipei, Taiwan; approval number: CHIACUC 104-05). Six-week-old male Wistar strain rats (BioLasco, Taipei, Taiwan) were housed in large plastic cages (Shineteh Instrument Co., Ltd. ). Rats are arbitrarily assigned to one group in the following groups, and the experimental animals (the number of samples is 120) are used in various experimental methods, that is, 3 groups of electroretinogram analysis [the number of samples is 16 in total, including: normal group (sample number number is 5); I / R+vehicle group (sample number is 5); I / R+Xuefu Zhuyu Decoction 1.35 group (the number of samples...

Embodiment 2

[0040] Example 2. Effect of Xuefu Zhuyu Decoction on the density of RGCs labeled with retrograde fluorescence.

[0041] After anesthesia, a 2 cm incision was made in the rat scalp and two small holes were drilled in the skull as described in previous techniques. (Peng PH, Chao HM, Juan SH, Chen CF, Liu JH and Ko ML.Pharmacologicalpreconditioning by low dose cobalt protoporphyrin induces heme oxygenase-1overexpression and induces retinal ischemia-reperfusion injury inrats.Curr.Eye Res.36(3):238 -246, 2011). Next, 2 microliters of 5% gold fluoride (Sigma-Aldrich, MO, USA) were injected via a micropipette at depths of 3.8, 4.0 and 4.2 mm below the skull. In all groups, gold fluoride was injected three days before sacrificing the rats. Retina were gently removed, fixed, dissected and processed as described in previous art. (PengPH, Chao HM, Juan SH, Chen CF, Liu JH and Ko ML.Pharmacological preconditioning by low dose cobalt protoporphyrin induces heme oxygenase-1overexpression...

Embodiment 3

[0043] Example 3. The effect of Xuefu Zhuyu Decoction on the thickness of various retinal layers stained with cresyl violet.

[0044] Animals were sacrificed and intracardiacly perfused with saline (weight volume concentration), the eyeballs were removed, fixed with 4% (weight volume concentration) paraformaldehyde and embedded in paraffin (Tissue-Tek TEC 5; Sakura, Alphen aan denRijn , Netherlands) and sliced ​​(5 microns). Retinal sections were stained with cresyl violet and examined under a light microscope (Leica, Heidelberg, Germany). Retinal sections were examined under a microscope and photographed at the same magnification (Ilford Pan-F plus film, 50ASA), and various retinal layer thicknesses were calculated from the photographs.

[0045] Whole-body retinal thickness (from inner limiting membrane to retinal pigment epithelium) and inner retinal thickness (from inner limiting membrane to inner nuclear layer) were measured to quantify retinal ischemic damage. All measu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a medical composition in preparation of a drug for preventing or treating diseases, obstacles or symptoms induced by ischemia retinae. The medical composition comprises 4.5 parts by weight of angelica sinensis, 1.5 parts by weight of radix bupleuri, 4.5 parts by weight of flowers carthami, 3 parts by weight of immature bitter orange, 4.5 parts by weight of radix achyranthis bidentatae, 1.5 parts by weight of liquorice, 2.25-2.3 parts by weight of ligusticum wallichii, 3 parts by weight of root of common peony, 2.25 to 2.3 parts by weight of platycodon grandiflorum, 6 parts by weight of peach kernel, and 4.5 parts by weight of rehmannia.

Description

technical field [0001] The invention relates to the application of a pharmaceutical composition in the preparation of medicines for preventing or treating retinal ischemia. Background technique [0002] Central retinal artery occlusion (CRAO), central retinal vein occlusion (CRVO), branch retinal artery occlusion (branch retinal artery occlusion, BRAO), branch retinal vein occlusion (branch retinal vein occlusion, BRVO), Glaucoma and age-related macular degeneration (AMD) are both associated with retinal ischemia. All of these diseases can lead to serious sequelae, therefore, the control of retinal ischemia is crucial. [0003] Neurons located in the inner retina, such as retinal ganglion cells (RGCs) and amacrine cells, and their neuronal processes are susceptible to ischemia / reperfusion (I / R) . Vimentin immunoreactivity has been shown to increase in Müller cells after I / R. Ischemia induces angiogenesis. Furthermore, in the retina, angiogenesis is often disorganized an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/804A61P9/10A61P3/10A61P27/02A61P27/06
CPCA61K36/21A61K36/232A61K36/233A61K36/236A61K36/286A61K36/346A61K36/484A61K36/65A61K36/71A61K36/736A61K36/752A61K36/804A61K2300/00
Inventor 赵效明
Owner 赵效明